FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…
Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
FAST NEWS: Kintor Pharma Soars on Good Results for Covid Drug
The latest: Kintor Pharmaceutical Ltd. (9939.HK) on Wednesday announced positive results from a Phase 3 clinical trial for its drug Proxalutamide for the treatment of mild-to-moderate ambulatory Covid-19 patients, saying…
RELATED ARTICLES
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
